C12Y 107/03003
Factor-independent urate hydroxylase , i.e. uricase
Official title: Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
C12Y107/03003 (Factor-independent urate hydroxylase , i.e. uricase) appears on 65 US grants and 146 published applications in this corpus.
Search patents in C12Y- Granted patents
- 65
- Published applications
- 146
- Assignees
- 61
- Inventors
- 226
- Latest grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 1 | 1 |
| 2004 | 0 | 1 |
| 2005 | 0 | 2 |
| 2006 | 1 | 0 |
| 2007 | 1 | 2 |
| 2008 | 0 | 2 |
| 2009 | 1 | 4 |
| 2010 | 3 | 5 |
| 2011 | 4 | 6 |
| 2012 | 6 | 8 |
| 2013 | 5 | 3 |
| 2014 | 1 | 3 |
| 2015 | 2 | 4 |
| 2016 | 2 | 2 |
| 2017 | 2 | 10 |
| 2018 | 5 | 6 |
| 2019 | 0 | 6 |
| 2020 | 4 | 9 |
| 2021 | 3 | 7 |
| 2022 | 2 | 10 |
| 2023 | 4 | 22 |
| 2024 | 4 | 13 |
| 2025 | 4 | 9 |
| 2026 | 9 | 11 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Method for preparing polyethylene glycol-modified urate oxidase25 Aug 2026US 12,714,741 B2Hangzhou Grand Biologic Pharmaceutical Inc.
- Gout flare prevention methods using IL-1β blockers25 Aug 2026US 12,715,915 B2
- Therapeutic engineered microbial cell system and methods for treating hyperuricemia and gout11 Aug 2026US 12,703,849 B2Unlocked Labs
- Methods of treating diseases associated with elevated uric acid11 Aug 2026US 12,703,857 B2Protalix Ltd.
- Modified uricase and uses thereof7 Jul 2026US 12,674,146 B2Protalix Ltd.
- Novel uricase variants and methods of use thereof8 Oct 2026US 2026/0308536 A1Insmed Incorporated
- Combination therapies of prednisone and uricase molecules and uses thereof24 Sep 2026US 2026/0284151 A1Horizon Therapeutics USA, Inc.
- Modified uricase and uses thereof24 Sep 2026US 2026/0286318 A1Protalix Ltd.
- Composition and Method for Synthesizing Pegylated Uricase-Drug Conjugates to Mitigate Anti-Drug Antibody and Their Therapeutic Use27 Aug 2026US 2026/0248931 A1Oncoc4, Inc.
- Formulations and doses of pegylated uricase20 Aug 2026US 2026/0242769 A1Cartesian Therapeutics, Inc.
Most cited
By later US patents
- PEG-urate oxidase conjugates and use thereof100US 6,576,235 B1Duke University · 2003
- Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof44US 8,129,330 B2Mountain View Pharmaceuticals, Inc. · 2012
- Urate oxidase33US 7,056,713 B1Duke University · 2006
- Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy33US 9,377,454 B2Crealta Pharmaceuticals LLC · 2016
- PEG-urate oxidase conjugates and use thereof29US 7,723,089 B2Duke University · 2010